{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:55:21Z","timestamp":1791071721832,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":77,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783540732587","type":"print"},{"value":"9783540732594","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008]]},"DOI":"10.1007\/978-3-540-73259-4_6","type":"book-chapter","created":{"date-parts":[[2007,12,10]],"date-time":"2007-12-10T16:25:20Z","timestamp":1197303920000},"page":"131-150","source":"Crossref","is-referenced-by-count":68,"title":["Therapeutic Anti-VEGF Antibodies"],"prefix":"10.1007","author":[{"given":"S.","family":"Lien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. B.","family":"Lowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"6_CR1_Ref","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis AP, Miller JW, Bernal MT, D\u2019Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450","journal-title":"Am J Ophthalmol"},{"key":"6_CR2_Ref","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","volume":"114","author":"AP Adamis","year":"1996","unstructured":"Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D\u2019Amore PA, Miller JW (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemiaassociated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66-71","journal-title":"Arch Ophthalmol"},{"key":"6_CR3_Ref","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487","journal-title":"N Engl J Med"},{"key":"6_CR4_Ref","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/nm1095-1024","volume":"1","author":"T Alon","year":"1995","unstructured":"Alon T, Hemo I, Itin A, Pe\u2019er J, Stone J, Keshet E (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024-1028","journal-title":"Nat Med"},{"key":"6_CR5_Ref","doi-asserted-by":"publisher","first-page":"10678","DOI":"10.1074\/jbc.272.16.10678","volume":"272","author":"M Baca","year":"1997","unstructured":"Baca M, Presta LG, O\u2019Connor SJ, Wells JA (1997) Antibody humanization using monovalent phage display. J Biol Chem 272:10678-10684","journal-title":"J Biol Chem"},{"key":"6_CR6_Ref","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","volume":"142","author":"ZF Bashshur","year":"2006","unstructured":"Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1-9","journal-title":"Am J Ophthalmol"},{"key":"6_CR7_Ref","first-page":"4032","volume":"56","author":"P Borgstrom","year":"1996","unstructured":"Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56:4032-4039","journal-title":"Cancer Res"},{"key":"6_CR8_Ref","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Eng J Med 355:1432-1444","journal-title":"New Eng J Med"},{"key":"6_CR9_Ref","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR10_Ref","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1006\/jmbi.1999.3192","volume":"293","author":"Y Chen","year":"1999","unstructured":"Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB (1999) Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinitymatured Fab in complex with antigen. J Mol Biol 293:865-881","journal-title":"J Mol Biol"},{"key":"6_CR11_Ref","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/342877a0","volume":"342","author":"C Chothia","year":"1989","unstructured":"Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR et al. (1989) Conformations of immunoglobulin hypervariable regions. Nature 342:877-883","journal-title":"Nature"},{"key":"6_CR12_Ref","doi-asserted-by":"crossref","first-page":"16317","DOI":"10.1016\/S0021-9258(18)42003-0","volume":"267","author":"KP Claffey","year":"1992","unstructured":"Claffey KP, Wilkison WO, Spiegelman BM (1992) Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J Biol Chem 267:16317-16322","journal-title":"J Biol Chem"},{"key":"6_CR13_Ref","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1084\/jem.172.6.1535","volume":"172","author":"M Clauss","year":"1990","unstructured":"Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D (1990) Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545","journal-title":"J Exp Med"},{"key":"6_CR14_Ref","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/science.1312256","volume":"255","author":"C de Vries","year":"1992","unstructured":"de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991","journal-title":"Science"},{"key":"6_CR15_Ref","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/1523-1747.ep12312542","volume":"105","author":"M Detmar","year":"1995","unstructured":"Detmar M, Yeo KT, Nagy JA, Van de Water L, Brown LF, Berse B, Elicker BM, Ledbetter S, Dvorak HF (1995) Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 105:44-50","journal-title":"J Invest Dermatol"},{"key":"6_CR16_Ref","doi-asserted-by":"crossref","first-page":"C1367","DOI":"10.1152\/ajpcell.2001.280.6.C1367","volume":"280","author":"Y Dor","year":"2001","unstructured":"Dor Y, Porat R, Keshet E (2001) Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 280:C1367-C1374","journal-title":"Am J Physiol Cell Physiol"},{"key":"6_CR17_Ref","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611","journal-title":"Endocr Rev"},{"key":"6_CR18_Ref","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/70928","volume":"5","author":"N Ferrara","year":"1999","unstructured":"Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359-1364","journal-title":"Nat Med"},{"key":"6_CR19_Ref","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676","journal-title":"Nat Med"},{"key":"6_CR20_Ref","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","volume":"161","author":"N Ferrara","year":"1989","unstructured":"Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-858","journal-title":"Biochem Biophys Res Commun"},{"key":"6_CR21_Ref","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400","journal-title":"Nat Rev Drug Discov"},{"key":"6_CR22_Ref","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Eng J Med 285:1182-1186","journal-title":"N Eng J Med"},{"key":"6_CR23_Ref","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.1074\/jbc.M507783200","volume":"281","author":"G Fuh","year":"2006","unstructured":"Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C (2006) Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 281:6625-6631","journal-title":"J Biol Chem"},{"key":"6_CR24_Ref","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","volume":"46","author":"J Gaudreault","year":"2005","unstructured":"Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726-733","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6_CR25_Ref","first-page":"2142","volume":"1","author":"J Gaudreault","year":"1999","unstructured":"Gaudreault J, Webb W, Van Hoy M (1999) Pharmacokinetics and retinal distribution of AMD rhuFab V2 after intravitreal administration in rabbits. AAPS Pharm Sci Suppl 1:2142","journal-title":"AAPS Pharm Sci Suppl"},{"key":"6_CR26_Ref","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","volume":"65","author":"HP Gerber","year":"2005","unstructured":"Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680","journal-title":"Cancer Res"},{"key":"6_CR27_Ref","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1073\/pnas.0611492104","volume":"104","author":"HP Gerber","year":"2007","unstructured":"Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N (2007) Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 104:3478-3483","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR28_Ref","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1084\/jem.136.2.261","volume":"136","author":"MA Gimbrone","year":"1972","unstructured":"Gimbrone MA, Leapmaan SB, Cotran RS, Folkman J (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261-276","journal-title":"J Exp Med"},{"key":"6_CR29_Ref","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1084\/jem.193.9.1005","volume":"193","author":"K Hattori","year":"2001","unstructured":"Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S (2001) Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193:1005-1014","journal-title":"J Exp Med"},{"key":"6_CR30_Ref","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1210\/mend-5-12-1806","volume":"5","author":"KA Houck","year":"1991","unstructured":"Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814","journal-title":"Mol Endocrinol"},{"key":"6_CR31_Ref","doi-asserted-by":"crossref","first-page":"26031","DOI":"10.1016\/S0021-9258(18)35712-0","volume":"267","author":"KA Houck","year":"1992","unstructured":"Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037","journal-title":"J Biol Chem"},{"key":"6_CR32_Ref","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 350:2335-2342","journal-title":"N Eng J Med"},{"key":"6_CR33_Ref","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3816\/CCC.2006.n.023","volume":"6","author":"HI Hurwitz","year":"2006","unstructured":"Hurwitz HI, Honeycutt W, Haley S, Favaro J (2006) Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: Case report. Clin Colorectal Cancer 6:66-69","journal-title":"Clin Colorectal Cancer"},{"key":"6_CR34_Ref","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/archopht.123.4.509","volume":"123","author":"D Husain","year":"2005","unstructured":"Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, Connolly EJ, Michaud N, Gragoudas ES, O\u2019Neill CA, Beyer JC, Miller JW (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123:509-516","journal-title":"Arch Ophthalmol"},{"key":"6_CR35_Ref","first-page":"891","volume":"42","author":"AG Ide","year":"1939","unstructured":"Ide AG, Baker NH, Warren SL (1939) Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol 42:891-899","journal-title":"Am J Roentgenol"},{"key":"6_CR36_Ref","volume-title":"Sequences of proteins of immunological interest","author":"EA Kabat","year":"1991","unstructured":"Kabat EA, Wu TT, Perry H, Gottesmann KS, Foeller C (1991) Sequences of proteins of immunological interest. Public Health Service, National Institutes of Health, Bethesda, MD"},{"key":"6_CR37_Ref","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1167\/iovs.04-0087","volume":"47","author":"IK Kim","year":"2006","unstructured":"Kim IK, Husain D, Michaud N, Connolly EJ, Lane AM, Durrant K, Hafezi-Moghadam A, Gragoudas ES, O\u2019Neill CA, Beyer JC, Miller JW (2006) Effect of the intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroids. Invest Ophthalmol Vis Sci 47:357-363","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6_CR38_Ref","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/08977199209023937","volume":"7","author":"KJ Kim","year":"1992","unstructured":"Kim KJ, Li B, Houck K, Winer J, Ferrara N (1992) The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53-64","journal-title":"Growth Factors"},{"key":"6_CR39_Ref","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844","journal-title":"Nature"},{"key":"6_CR40_Ref","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","volume":"120","author":"MG Krzystolik","year":"2002","unstructured":"Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O\u2019Neill CA, Miller JW (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120:338-346","journal-title":"Arch Ophthalmol"},{"key":"6_CR41_Ref","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jmb.2004.05.051","volume":"340","author":"CV Lee","year":"2004","unstructured":"Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G (2004) High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 340:1073-1093","journal-title":"J Mol Biol"},{"key":"6_CR42_Ref","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309","journal-title":"Science"},{"key":"6_CR43_Ref","doi-asserted-by":"publisher","first-page":"29823","DOI":"10.1074\/jbc.M002015200","volume":"275","author":"B Li","year":"2000","unstructured":"Li B, Fuh G, Meng G, Xin X, Gerritsen ME, Cunningham B, de Vos AM (2000) Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization. J Biol Chem 275:29823-29828","journal-title":"J Biol Chem"},{"key":"6_CR44_Ref","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1074\/jbc.M508199200","volume":"281","author":"WC Liang","year":"2006","unstructured":"Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281:951-961","journal-title":"J Biol Chem"},{"key":"6_CR45_Ref","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1056\/NEJMc063011","volume":"356","author":"G Liew","year":"2007","unstructured":"Liew G, Mitchell P (2007) Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 356:747-750","journal-title":"N Eng J Med"},{"key":"6_CR46_Ref","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","volume":"288","author":"YS Lin","year":"1999","unstructured":"Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378","journal-title":"J Pharmacol Exp Ther"},{"key":"6_CR47_Ref","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archopht.1994.01090230090028","volume":"112","author":"F Malecaze","year":"1994","unstructured":"Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J (1994) Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112:1476-1482","journal-title":"Arch Ophthalmol"},{"key":"6_CR48_Ref","first-page":"921","volume":"56","author":"O Melnyk","year":"1996","unstructured":"Melnyk O, Shuman MA, Kim KJ (1996) Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56:921-924","journal-title":"Cancer Res"},{"key":"6_CR49_Ref","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035-1047","journal-title":"Ophthalmology"},{"key":"6_CR50_Ref","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0092-8674(93)90573-9","volume":"72","author":"B Millauer","year":"1993","unstructured":"Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846","journal-title":"Cell"},{"key":"6_CR51_Ref","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/019262339902700507","volume":"27","author":"J Mordenti","year":"1999","unstructured":"Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27:536-544","journal-title":"Toxicol Pathol"},{"key":"6_CR52_Ref","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0969-2126(98)00116-6","volume":"6","author":"YA Muller","year":"1998","unstructured":"Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM (1998) VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 A\u02da resolution and mutational analysis of the interface. Structure 6:1153-1167","journal-title":"Structure"},{"key":"6_CR53_Ref","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S0969-2126(97)00284-0","volume":"5","author":"YA Muller","year":"1997","unstructured":"Muller YA, Christinger HW, Keyt BA, de Vos AM (1997) The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A\u02da resolution: Multiple copy flexibility and receptor binding. Structure 5:1325-1338","journal-title":"Structure"},{"key":"6_CR54_Ref","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1006\/jmbi.2001.5370","volume":"316","author":"B Pan","year":"2002","unstructured":"Pan B, Li B, Russell SJ, Tom JY, Cochran AG, Fairbrother WJ (2002) Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor. J Mol Biol 316:769-787","journal-title":"J Mol Biol"},{"key":"6_CR55_Ref","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1091\/mbc.4.12.1317","volume":"4","author":"JE Park","year":"1993","unstructured":"Park JE, Keller GA, Ferrara N (1993) The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4:1317-1326","journal-title":"Mol Biol Cell"},{"key":"6_CR56_Ref","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599","journal-title":"Cancer Res"},{"key":"6_CR57_Ref","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.1073\/pnas.90.16.7533","volume":"90","author":"TP Quinn","year":"1993","unstructured":"Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT (1993) Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90:7533-7537","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR58_Ref","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/092986706777585059","volume":"13","author":"G Ranieri","year":"2006","unstructured":"Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic. Curr Med Chem 13:1845-1857","journal-title":"Curr Med Chem"},{"key":"6_CR59_Ref","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ophtha.2006.01.027","volume":"113","author":"PJ Rosenfeld","year":"2006a","unstructured":"Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N (2006a) Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 113:623-632","journal-title":"Ophthalmology"},{"key":"6_CR60_Ref","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005a","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005a) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331-335","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"6_CR61_Ref","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","volume":"112","author":"PJ Rosenfeld","year":"2005b","unstructured":"Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N (2005b) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048-1053","journal-title":"Ophthalmology"},{"key":"6_CR62_Ref","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ohc.2006.05.009","volume":"19","author":"PJ Rosenfeld","year":"2006b","unstructured":"Rosenfeld PJ, Rich RM, Lalwani GA (2006b) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19:361-372","journal-title":"Ophthalmol Clin North Am"},{"key":"6_CR63_Ref","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006c","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006c) Ranibizumab for neovascular age-related macular degeneration. New Eng J Med 355:1419-1431","journal-title":"New Eng J Med"},{"key":"6_CR64_Ref","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/019262339902700115","volume":"27","author":"AM Ryan","year":"1999","unstructured":"Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, O\u2019Neill CA (1999) Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27:78-86","journal-title":"Toxicol Pathol"},{"key":"6_CR65_Ref","doi-asserted-by":"publisher","first-page":"4421s","DOI":"10.1158\/1078-0432.CCR-06-0796","volume":"12","author":"A Sandler","year":"2006","unstructured":"Sandler A, Herbst R (2006) Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12:4421s-4425s","journal-title":"Clin Cancer Res"},{"key":"6_CR66_Ref","doi-asserted-by":"publisher","first-page":"1306-1314","DOI":"10.1016\/S0161-6420(03)00452-4","volume":"110","author":"UM Schmidt-Erfurth","year":"2003","unstructured":"Schmidt-Erfurth UM, Michels S (2003) Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 110:1306-1314","journal-title":"Ophthalmology"},{"key":"6_CR67_Ref","first-page":"519","volume":"5","author":"M Shibuya","year":"1990","unstructured":"Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5:519-524","journal-title":"Oncogene"},{"key":"6_CR68_Ref","first-page":"1334","volume":"37","author":"DT Shima","year":"1996","unstructured":"Shima DT, Gougos A, Miller JW, Tolentino M, Robinson G, Adamis AP, D\u2019Amore PA (1996) Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 37:1334-1340","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6_CR69_Ref","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-745","journal-title":"Cell"},{"key":"6_CR70_Ref","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc863","volume":"2","author":"SA Stacker","year":"2002","unstructured":"Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K (2002) Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2:573-583","journal-title":"Nat Rev Cancer"},{"key":"6_CR71_Ref","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","volume":"15","author":"J Stone","year":"1995","unstructured":"Stone J, Itin A, Alon T, Pe\u2019er J, Gnessin H, Chan-Ling T, Keshet E (1995) Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15:4738-4747","journal-title":"J Neurosci"},{"key":"6_CR72_Ref","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/bies.20092","volume":"26","author":"E Storkebaum","year":"2004","unstructured":"Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: Once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26:943-954","journal-title":"Bioessays"},{"key":"6_CR73_Ref","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/0006-291X(92)90483-2","volume":"187","author":"BI Terman","year":"1992","unstructured":"Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579-1586","journal-title":"Biochem Biophys Res Commun"},{"key":"6_CR74_Ref","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1016\/S0021-9258(18)99049-6","volume":"266","author":"E Tischer","year":"1991","unstructured":"Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954","journal-title":"J Biol Chem"},{"key":"6_CR75_Ref","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1172\/JCI117857","volume":"95","author":"RS Warren","year":"1995","unstructured":"Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797","journal-title":"J Clin Invest"},{"key":"6_CR76_Ref","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0092-8674(00)80456-0","volume":"91","author":"C Wiesmann","year":"1997","unstructured":"Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM (1997) Crystal structure at 1.7 A\u02da resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91:695-704","journal-title":"Cell"},{"key":"6_CR77_Ref","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1345\/aph.1D470","volume":"38","author":"SD Zondor","year":"2004","unstructured":"Zondor SD, Medina PJ (2004) Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 38:1258-1264","journal-title":"Ann Pharmacother"}],"container-title":["Handbook of Experimental Pharmacology","Therapeutic Antibodies"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-540-73259-4_6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T14:00:03Z","timestamp":1737640803000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-540-73259-4_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"ISBN":["9783540732587","9783540732594"],"references-count":77,"URL":"https:\/\/doi.org\/10.1007\/978-3-540-73259-4_6","relation":{},"ISSN":["0171-2004"],"issn-type":[{"value":"0171-2004","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}